Compare IMNM & INOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | INOD |
|---|---|---|
| Founded | 2006 | 1988 |
| Country | United States | United States |
| Employees | N/A | 3000 |
| Industry | Medicinal Chemicals and Botanical Products | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2020 | 1996 |
| Metric | IMNM | INOD |
|---|---|---|
| Price | $18.76 | $35.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | $35.13 | ★ $111.50 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | 3.37 |
| EPS | N/A | ★ 1.13 |
| Revenue | $6,941,000.00 | ★ $86,775,000.00 |
| Revenue This Year | N/A | $42.87 |
| Revenue Next Year | N/A | $27.95 |
| P/E Ratio | ★ N/A | $32.14 |
| Revenue Growth | N/A | ★ 9.84 |
| 52 Week Low | $16.41 | $34.23 |
| 52 Week High | $30.06 | $125.14 |
| Indicator | IMNM | INOD |
|---|---|---|
| Relative Strength Index (RSI) | 46.46 | 32.21 |
| Support Level | $17.18 | $34.37 |
| Resistance Level | $23.30 | $47.79 |
| Average True Range (ATR) | 1.39 | 3.52 |
| MACD | 0.20 | -0.62 |
| Stochastic Oscillator | 25.98 | 7.62 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.